HC SVT 1001

Drug Profile

HC SVT 1001

Alternative Names: Adipose-derived-stem-cells-Salvat; Allogeneic-mesenchymal-stem-cells-Salvat

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SALVAT
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Pseudoarthrosis

Most Recent Events

  • 11 Jul 2016 HC SVT 1001 is still in phase I/II trial for Pseudarthrosis in Spain (EudraCT2013-000930-37) (NCT02483364)
  • 29 Apr 2014 Phase-I/II clinical trials in Pseudoarthrosis in Spain (Intraosseous, Implant) (EudraCT2013-000930-37)
  • 31 May 2010 Preclinical trials in Bone disorders in Spain (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top